![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
(MM) | NASDAQ:IDIX | NASDAQ | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.50 | 0.00 | 01:00:00 |
Idenix
Pharmaceuticals, Inc.
|
Delaware
|
000-49839
|
45-0478605
|
(State
or Other Juris-
diction
of Incorporation
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
60
Hampshire Street
Cambridge,
MA
|
02139
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
(d)
|
Exhibits
|
|
99.1
|
Press
Release, “Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2009
Financial Results,” dated October 29,
2009.
|
|
99.2
|
Press
Release, “Idenix Retains Worldwide Rights to Develop and Commercialize
IDX184 for the Treatment of HCV,” dated October 29,
2009
|
Idenix
Pharmaceuticals, Inc.
|
|||
Date: October
29, 2009
|
By:
|
/s/ Ronald C. Renaud, Jr. | |
Ronald
C. Renaud, Jr.
Chief
Financial Officer
|
Exhibit
No.
|
Description
|
99.1
|
Press release
“Idenix
Pharmaceuticals Reports Third Quarter and Nine Month 2009 Financial
Results,” dated October 29, 2009.
|
99.2
|
Press Release, “Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV,” dated October 29, 2009. |
1 Year (MM) Chart |
1 Month (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions